AU2020223467B2 - Cancer treatment - Google Patents

Cancer treatment

Info

Publication number
AU2020223467B2
AU2020223467B2 AU2020223467A AU2020223467A AU2020223467B2 AU 2020223467 B2 AU2020223467 B2 AU 2020223467B2 AU 2020223467 A AU2020223467 A AU 2020223467A AU 2020223467 A AU2020223467 A AU 2020223467A AU 2020223467 B2 AU2020223467 B2 AU 2020223467B2
Authority
AU
Australia
Prior art keywords
erdafitinib
daily
treatment
serum phosphate
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020223467A
Other languages
English (en)
Other versions
AU2020223467A1 (en
Inventor
Anjali Narayan Avadhani
Peter Marie Z. De Porre
Anne Elizabeth O'HAGAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2020223467A1 publication Critical patent/AU2020223467A1/en
Application granted granted Critical
Publication of AU2020223467B2 publication Critical patent/AU2020223467B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020223467A 2019-02-12 2020-02-11 Cancer treatment Active AU2020223467B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19156806.2 2019-02-12
EP19156806 2019-02-12
EP19176575 2019-05-24
EP19176575.9 2019-05-24
PCT/EP2020/053490 WO2020165181A1 (en) 2019-02-12 2020-02-11 Cancer treatment

Publications (2)

Publication Number Publication Date
AU2020223467A1 AU2020223467A1 (en) 2021-08-05
AU2020223467B2 true AU2020223467B2 (en) 2025-12-04

Family

ID=69467563

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020223467A Active AU2020223467B2 (en) 2019-02-12 2020-02-11 Cancer treatment

Country Status (16)

Country Link
US (1) US20220168298A1 (enExample)
EP (1) EP3923942A1 (enExample)
JP (1) JP2022521173A (enExample)
KR (1) KR20210126654A (enExample)
CN (1) CN113423402A (enExample)
AU (1) AU2020223467B2 (enExample)
BR (1) BR112021015686A2 (enExample)
CA (1) CA3126959A1 (enExample)
IL (1) IL285466A (enExample)
JO (1) JOP20210216A1 (enExample)
MA (1) MA54932A (enExample)
MX (1) MX2021009670A (enExample)
PH (1) PH12021551949A1 (enExample)
SG (1) SG11202107850VA (enExample)
TW (1) TWI863962B (enExample)
WO (1) WO2020165181A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117083283A (zh) * 2020-12-11 2023-11-17 医睿世康药业研发公司 用于癌症治疗的联合疗法
US20240058352A1 (en) * 2020-12-11 2024-02-22 Erasca, Inc. Combination therapies for the treatment of cancer
CN112957368A (zh) * 2021-04-02 2021-06-15 南昌大学 一种司维拉姆的新用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018141921A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202200177T1 (it) * 2014-09-26 2022-05-12 Janssen Pharmaceutica Nv Uso di gruppi di geni mutanti del fgfr nell'identificazione di pazienti affetti da cancro che saranno responsivi al trattamento con un inibitore del fgfr
JOP20200201A1 (ar) * 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
CA3002560A1 (en) * 2015-10-23 2017-04-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018141921A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BELLMUNT ET AL: "Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens", J CLIN ONCOL, vol. 28(11), (2010-04-10), pages 1850-1855 *

Also Published As

Publication number Publication date
SG11202107850VA (en) 2021-08-30
AU2020223467A1 (en) 2021-08-05
IL285466A (en) 2021-09-30
JP2022521173A (ja) 2022-04-06
WO2020165181A1 (en) 2020-08-20
US20220168298A1 (en) 2022-06-02
TWI863962B (zh) 2024-12-01
KR20210126654A (ko) 2021-10-20
JOP20210216A1 (ar) 2023-01-30
PH12021551949A1 (en) 2022-07-18
MA54932A (fr) 2021-12-22
CN113423402A (zh) 2021-09-21
EP3923942A1 (en) 2021-12-22
TW202045173A (zh) 2020-12-16
BR112021015686A2 (pt) 2021-10-26
MX2021009670A (es) 2021-09-08
CA3126959A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
AU2018216969B2 (en) Cancer treatment
WO2018141921A1 (en) Cancer treatment
AU2020223467B2 (en) Cancer treatment
AU2018278271A1 (en) FGFR2 inhibitors for the treatment of cholangiocarcinoma
TWI734734B (zh) 一種ｅｇｆｒ/ｈｅｒ２受體酪氨酸激酶抑制劑在製備治療ｈｅｒ２突變癌症藥物中的用途
EP4011452A1 (en) Therapeutic agent for cancer having resistance to anti-ccr4 antibody
HK40103983A (en) Cancer treatment
HK40018978A (en) Cancer treatment
HK40018978B (en) Cancer treatment
EP3946341A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
US20230321102A1 (en) TREATMENT OF CANCER USING COMBINATION THERAPIES COMPRISING GDC-6036 and GDC-0077
HK40013982A (en) Cancer treatment